anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As with all intramuscular preparations, DEMEROL intramuscular injection should be injected well within the body of a large muscle.

Supraventricular Tachycardias. Meperidine should be used with caution in patients with atrial flutter and other supraventricular tachycardias because of a possible vagolytic action which may produce a significant increase in the ventricular response rate.

Convulsions. Meperidine may aggravate preexisting convulsions in patients with convulsive disorders. If dosage is escalated substantially above recommended levels because of tolerance development, convulsions may occur in individuals without a history of convulsive disorders.

Acute Abdominal Conditions. The administration of meperidine or other narcotics may obscure the diagnosis or clinical course in patients with acute abdominal conditions.

Special Risk Patients. Meperidine should be given with caution and the initial dose should be reduced in certain patients such as the debilitated, and those with severe impairment of hepatic or renal function, hypothyroidism, Addison’s disease, and prostatic hypertrophy or urethral stricture.
OBJECTIVES: I. Determine whether endogenous cellular immunity to a particular tumor-specific mutated p53 or ras protein is present in patients with tumors expressing mutant p53 or ras. II. Determine whether vaccination with antigen-presenting cells pulsed in vitro with synthetic peptide corresponding to the tumor's p53 or ras mutation in the presence of sargramostim (GM-CSF) can induce or boost patient cellular immunity to the mutated peptide in this patient population. III. Assess the type and characteristics of the cellular immunity generated. IV. Determine whether in vivo-primed T-cells generated against the p53 or ras mutation, expanded in vitro with corresponding peptide, and infused with subcutaneous interleukin-2 can enhance the activity of specific cytotoxic T-lymphocyte immune response and/or tumor response in these patients.

OUTLINE: Patients are assigned to 1 of 2 treatment regimens. The first 5 patients accrued are assigned to Regimen A. Three weeks after all 5 patients are enrolled, additional patients are accrued and assigned to Regimen B. All patients undergo peptide hypersensitivity testing with the peptide they will be treated with prior to each vaccination. Regimen A: Two days prior to each vaccination, peripheral blood mononuclear cells (PBMC) are harvested. PBMC are incubated for 48 hours with either patient-specific mutant p53 or ras peptide fragments and sargramostim (GM-CSF). The antigen-presenting cells (APC) are irradiated prior to use. APC are reinfused on day 0. Treatment repeats after 3 weeks and then every 6 weeks for a total of 4 vaccinations. Regimen B: Patients are vaccinated with APC as in Regimen A. PBMC are harvested prior to the first APC vaccination and 1 week after the second, third, and fourth APC vaccinations. PBMC are incubated for 7 days with either peptide the patient was vaccinated with (mutant p53 or ras peptide fragments) and interleukin-2 (IL-2). The peptide-activated lymphocytes (PAL) are reinfused over 1 hour 2 weeks after each APC vaccination. Patients receive IL-2 subcutaneously 5 days a week for 2 weeks beginning 4 hours after each PAL infusion. Patients in both regimens with stable or responding disease continue treatment every 6 weeks. Patients achieving complete response continue treatment for up to 1 additional year. Patients are followed at 1 and 2 months.

PROJECTED ACCRUAL: A maximum of 70 patients (5 per Regimen A, 28-65 per Regimen B) will be accrued for this study.
Weekly group phone calls for 6 months. Group phone calls will last about 45 minutes each. Phone calls will include groups of 12-18 participants.
PURPOSE:To obtain the subject composition preventing skin from getting dry after applied, by formulating specific glycerin derivative(s) in a skin external preparation containing a xanthine derivative, bipyridine derivative, etc., having anti-phlegmonic activity or leaning activity. CONSTITUTION:This skin external preparation composition contains at least one kind selected from xanthine derivatives, beta-adrenaline activity stimulants, alpha2-adrenaline activity suppressants and bipyridine derivatives and at least one kind selected from etherified compounds from glycerin or polyglycerin and monohydric alcohols anc polyglycerin fatty acid esters. The etherified compound is pref. a compound of formula I or II (R<1>-R<4> are each H, an aliphatic hydrocarbon or aromatic hydrocarbon; (n) is 0-60). The xanthine derivative, beta-adrenaline activity stimulant, alpha2-adrenaline activity suppressant, and bipyridine derivative, are pref. aminophyrin, isoproterenol, yohimbine, and amurinone, respectively.
Previous preclinical data and a prospective validated patient cohort have shown that patients with head and neck squamous cell carcinoma, whose tumours are hypoxic after 2 weeks of primary radiochmeotherapy, have a significantly lower chance of locoregional tumour control. The multi-center trial evaluates the value of radiation dose escalation based on hypoxia detection by 18F_misonidazole Positron Emission Tomography (18F-MISO-PET) for primary radiochemotherapy of head and neck squamous cell carcinoma. Patients negative for human papillomavirus (HPV) and with hypoxic tumours after 2 weeks of radiochemotherapy are randomized to completion of standard radiochemotherapy (70 Gy) or radiochemotherapy with escalated radiation dose (77 Gy). An additional interventional arm includes a carbon ion boost to 77 Gy. HPV positive tumours can be included in a control arm. Primary endpoint is local tumour control 2 years after radiochemotherapy. Secondary endpoints include acute and late toxicity (CTCAE 5.0), regional tumor control, overall survival, disease free survival, distant metastases, kinetics analysis of dynamic FMISO-PET scans, Quality of life (QoL). The hypothesis is that local tumour control 2 years after radiochemotherapy is higher in the dose escalated compared to the control arm.
<P>PROBLEM TO BE SOLVED: To provide a device for vaccinating a vaccine through the skin regarding the efficient device for medicating a chemical through the skin of a human being.  <P>SOLUTION: A chemical feeding device having a section for going through the skin is provided, which includes a chemical containing solid reservoir medium for which a skin puncturing member is coated with a reservoir medium. Alternatively, the skin puncturing member may consist of a solid chemical reservoir medium. The chemical feeding device is adjusted in such a manner that a chemical may be fed into a specified layer of the skin. Preferably, the feeding device includes the skin puncturing member which feeds the chemical to the epithelium or the dermis. The preferable reservoir medium includes saccharides, especially saccharides for stabilization such as a lactose which forms glass (an amorphous solid substance), a raffinose, a trehalose or a sucrose.  <P>COPYRIGHT: (C)2011,JPO&INPIT
All participants will be asked to consume 32 ounces daily of Mediterranean Lemonade. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
Neglected tropical diseases (NTDs) are a group of diseases mainly affecting people in low- and middle-income Countries. The aim of this study was to perform a bibliometric analysis of the scientific literature on NTDs. Using the MeSH database, we quantified the number of publications on MEDLINE targeting each NTD, which were published from 1 January 1999 to 31 January 2019. In order to weight the number of publications targeting a given NTD according to the total number of publications/year, we calculated a Yearly Publication Index (YPI) for each NTD/year. Linear regression was used to determine if there was a significant increase or decrease of YPI over time. In order to weight the number of publications according to disease burden (expressed in Disability-adjusted life years - DALYs) we calculated a DALYs-weighted Publication Index (DWPI) for each NTD. The highest absolute number of publications focused on leishmaniasis, dengue and Chagas disease; the lowest on tungiasis, dracunculiasis, chromoblastomycosis and yaws. The number of publications significantly increased for chikungunya, chromoblastomycosis, dengue, leishmaniasis, snakebite envenoming, and yaws. It significantly decreased for ascariasis, cysticercosis, echinococcosis, leprosy, lymphatic filariasis, mycetoma, onchocerciasis. Leprosy had the highest DWPI (i.e. the highest number of publication considering the burden of disease), followed by Chagas disease; lymphatic filariasis had the lowest, followed by onchocerciasis. Overall, lymphatic filariasis, onchocerciasis and ascariasis presented the worst scenario, with both very few publications compared with their disease burden and a decreasing number of publications.
Period 1 (Days 1 to 10): Following an overnight fast of at least 10 hours, participants will start a standardized meal and should consume the meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal on Day 1 of Period 1. Period 2 (Days 11 to 20): Participants will receive oral esomeprazole 40 mg once daily for 6 days (Days 11-16) in the morning after an overnight fast of at least 10 hours, and at least 1 hour before a regular breakfast; On Day 16, following an overnight fast of at least 10 hours, a single oral dose of 40 mg esomeprazole will be administered 1.5 hours prior to the start of a standardized meal. Following a standardized meal, a single oral 600 mg dose of alectinib will then be administered.
In the realm of agricultural sustainability, the utilization of plant genetic resources for enhanced disease resistance is paramount. Preservation efforts in genebanks are justified by their potential contributions to future crop improvement. To capitalize on the potential of plant genetic resources, we focused on a barley core collection from the German ex situ genebank and contrasted it with a European elite collection. The phenotypic assessment included 812 plant genetic resources and 298 elites, with a particular emphasis on four disease traits (Puccinia hordei, Blumeria graminis hordei, Ramularia collo-cygni, and Rhynchosporium commune). An integrated genome-wide association study, employing both Bayesian-information and linkage-disequilibrium iteratively nested keyway (BLINK) and a linear mixed model, was performed to unravel the genetic underpinnings of disease resistance. A total of 932 marker-trait associations were identified and assigned to 49 quantitative trait loci. The accumulation of novel and rare resistance alleles significantly bolstered the overall resistance level in plant genetic resources. Three plant genetic resources donors with high counts of novel/rare alleles and exhibiting exceptional resistance to leaf rust and powdery mildew were identified, offering promise for targeted pre-breeding goals and enhanced resilience in future varieties. Our findings underscore the critical contribution of plant genetic resources to strengthening crop resilience and advancing sustainable agricultural practices.
Long-term carcinogenicity studies have been carried out in mice (oral doses 30-150 mg/kg) and rats (oral doses 5-75 mg/kg). Results are pending.

Theophylline has been studied in Ames salmonella, in vivoand in vitrocytogenetics, micronucleus and Chinese hamster ovary test systems and has not been shown to be genotoxic. 

In a 14 week continuous breeding study, theophylline, administered to mating pairs of B6C3F 1mice at oral doses of 120, 270 and 500 mg/kg (approximately 1.0-3.0 times the human dose on a mg/m² basis) impaired fertility, as evidenced by decreases in the number of live pups per litter, decreases in the mean number of litters per fertile pair, and increases in the gestation period at the high dose as well as decreases in the proportion of pups born alive at the mid and high dose. In 13-week toxicity studies, theophylline was administered to F344 rats and B6C3F 1mice at oral doses of 40-300 mg/kg (approximately 2.0 times the human dose on a mg/m² basis). At the high dose, systemic toxicity was observed in both species including decreases in testicular weight.
The neuroinflammatory state may contribute to the pathogenesis of many mental disorders including schizophrenia. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor for activation of proteins involved in mitochondria quality control, such as Sirtuin3 (SIRT3). Our previous study has found that NAD+ supplement could rescue early life stress (ELS)-induced neuroinflammation and down-regulation of SIRT3 in adult offspring. However, it is unclear whether SIRT3 is the key to the neuroprotective effects of NAD+ supplement in this animal model of schizophrenia. The present study used 24 h maternal separation (MS) as ELS to Wistar rat pups on the postnatal day (PND) 9. Schizophrenia-like behaviors and memory impairments were detected by behavioral tests. Microglial activation, pro-inflammatory cytokine expression, and NAD+/SIRT3 expression were detected in the prefrontal cortex and hippocampus. Meanwhile, NAM (a precursor of NAD+), and the SIRT3 activator Honokiol (HNK), and the SIRT3 inhibitor 3-TYP were used as an intervention in vivo. Our results showed that ELS could induce schizophrenia-like behaviors and M1 microglial activation, NAD+ decline, lower expression of SIRT3, and increased acetylated superoxide dismutase 2 expression at the adult stage. NAD+ supplement or HNK administration could block this process and normalize the behavioral alterations of the MS animals. 3-TYP administration in the control group and the NAM-treated MS rats caused M1 microglial activation and cognitive deficits. Our results demonstrated that SIRT3 mediated the stabilizing effect of NAD+ on normalizing M1 microglial activation and behavioral phenotypes in MS rats.
The present invention relates to a medicine for treating hepatitis B viruses, which is mainly prepared from bupleurum root, baical skullcap root and white peony root according to the teachings of deceased great masters. Hepatitis B is caused by yang deficiency, and thus, a yang deficiency treating medicine, namely minor bupleurum root decoction, is used. In Japanese, a plurality of patients with hepatitis B are cured by using the minor bupleurum root decoction. According to the experience of predecessors, virgate wormwood herb and poria from Yunnan of China are matched for clearing heat-toxin, invigorating the spleen and promoting dampness; red sage root has the function of promoting blood circulation for removing blood stasis; raw fleece-flower root and astragalus root have the functions of nourishing the liver and kidney, enhancing immunological competence, inducing interferon, lowering aminopherase, promoting liver cell regeneration, accelerating tissue repair of a focus and resisting hepatic fibrosis so as to obtain the principle of supporting healthy energy to eliminate evil. The medicine has the advantages of high therapeutic effect, no recurrence, no toxic or side effect, low cost and no relapse after cure. The effective rate of the medicine can reach 85%, and the cure rate can reach more than 80%.
Target tissue may be removed from a subject using a cannula (30) that has an interior cavity and an orifice (37) configured to permit material to enter the cavity. This is accomplished by generating a negative pressure in the cavity so that a portion of the tissue is drawn into the orifice. Fluid is then delivered, via a conduit (35), so that the fluid exits the conduit within the cavity and impinges against the portion of the tissue that was drawn into the orifice. The fluid is delivered at a pressure and temperature that causes the tissue to soften, liquefy, or gellify. The tissue that has been softened, liquefied, or gel I if ied is then suctioned away. The matter that was suctioned away is collected and gravity separated, and fat that is suitable for implantation in the subject is extracted from a selected layer (e.g., the top half) of the supernatant of the gravity-separated matter.
The invention belongs to a traditional Chinese medicine and discloses a traditional Chinese medicine for treating chronic gastritis. The traditional Chinese medicine for treating chronic gastritis comprises 3-6g of Ligusticum chuanxiong Hort., 10-14g of pilose asiabell root, 8-12g of coptis root, 8-12g of costusroot and 4-8g of licorice. The above traditional Chinese medicines are grinded together into fine powder. 20g of the traditional Chinese medicine is taken with warm boiled water each time, two times a day. In a treatment course, five doses of the traditional Chinese medicine are taken continuously. The traditional Chinese medicine is designed according to the traditional Chinese medicine syndrome differentiation theory, has a simple formula, utilizes the easily acquired raw materials, has a low cost, high curative effects and no toxic or side effect, and can regulate the human body to a normal state.
Sitagliptin is given at a dose of 100 mg/m2 qd for 12 weeks. Danazol is given at 200mg bid for 12 weeks.
Inhaled NO (160 ppm) before and after the work shift. Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
Liver disease has become an important risk factor for global health. Resveratrol (Res) is a natural polyphenol which is widely found in foods and has a variety of biological activities. This study investigated the role of the microbiota-gut-liver axis in the Res relieving the liver fibrosis induced by inorganic mercury exposure. Twenty-eight mice were divided into four groups (n = 7) and treated with mercuric chloride and/or Res for 24 weeks, respectively. The results showed that Res mitigated the ileum injury induced by inorganic mercury and restrained LPS and alcohol entering the body circulation. Network pharmacological and molecular analyses showed that Res alleviated oxidative stress, metabolism disorders, inflammation, and hepatic stellate cell activation in the liver. In conclusion, Res alleviates liver fibrosis induced by inorganic mercury via activating the Sirt1/PGC-1α signaling pathway and regulating the microbial-gut-liver axis, particularly, increasing the relative enrichment of Bifidobacterium in the intestinal tract.
1,211,747. Cephalosporins. CIBA Ltd. 19 Dec., 1967 [20 Dec., 1966; 28 April, 1967; 30 Oct., 1967], No. 57614/67. Heading C2A. The invention comprises cephalosporins of Formula I or a salt thereof, wherein R 1  and R 2  each stands for halogen, R 3  is OH which is free or esterified by a carboxylic acid and in which O atoms may be replaced by S atoms, an unsubstituted or N-substituted carbamoyloxy group in which O may be replaced by S, or a quaternary amino group, and R 4  is OH or a negatively charged O atom. Typical compounds are 7-dichloroacetylamino cephalosporanic acid, 3 - desacetoxymethyl - 3 - pyridinomethyl - 7 - dichloroacetylamino-cephalosporanic acid and their sodium or potassium salts. The cephalosporins are prepared by the acylation at the 7-amino N by the group in which R 1  and R 2  have the above meanings, of a compound of formula in which R 3  and R 4  have the above meanings, and, if desired, in a resulting compound in which R 3  represents OH esterified by a carboxylic acid and in which O may be replaced by S, such R 3  group is converted in per se conventional manner into the free OH group or carbamoyloxy in which O may be replaced by S, or a quaternary amino group. Acylation may be by a mixed anhydride of trichloracetic acid and an acetic acid of formula The compounds have antibacterial activity. Cephalosporins of Formula I may be incorporated in pharmaceutical compositions for oral, topical or parenteral use. They may be added to aminal feeds. Specifications 912,541, 1,012,943, 1,059,562, 1,066,347, 1,080,904, 1,101,423 and 1,101,424 are referred to.
With the current unmet demand for effective pain relief, analgesics without major central adverse effects are highly appealing, such as peripherally restricted kappa-opioid receptor (KOR) agonists. In this study, Conorphin-66, an analog of the selective KOR peptide agonist Conorphin T, was pharmacologically characterized in a series of experiments, with CR845 serving as the reference compound. Firstly, in vitro functional assay indicated that Conorphin-66 selectively activates KOR and exhibits weak β-arrestin2 signaling bias (-1.54 versus -4.35 for CR845). Additionally, subcutaneous Conorphin-66 produced potent antinociception in mouse pain models with ED50 values ranged from 0.02 to 3.28 μmol/kg, including tail-flick test, post-operative pain, formalin pain, and acetic acid-induced visceral pain. Similarly, CR845 exert potent antinociception in mouse pain models ranged from 0.15 to 1.47 μmol/kg. Notably, antagonism studies revealed that the analgesic effects of Conorphin-66 were mainly mediated by the peripheral KOR. Furthermore, Conorphin-66 produced non-tolerance-forming antinociception over 8 days. Unlike CR845, subcutaneous Conorphin-66 did not promote the sedation, anxiogenic effects, depressive-like effects, but did exhibit diuretic activity. Further study showed that Conorphin-66 does not have apparent antipruritic effects in an acute itch model. Overall, Conorphin-66 emerges as a novel peripherally restricted KOR agonist that produced potent antinociception with reduced side effects.
PROBLEM TO BE SOLVED: To obtain the subject composition stable for a long period of time even under high temperatures, little in the lowering of viscosity, good in spreadability on hair and skin by including a non-neutralized crosslinked acrylic acid polymer and an organic acid containing glycolic acid as a main component. SOLUTION: This composition contains (A) a non-neutralized crosslinked acylic acid polymer having a mol.wt. of 2000000-4000000 (e.g. a crosslinked acrylic acid homopolylmer or copolymer, concretely crosslinked polyacrylic acid having a mol.wt. of 4000000) as a gel-forming agent in an amount of >=1 wt.%, preferably <=5 wt.%, and (B) an organic acid containing glycolic acid as a main component (e.g. the glycolic acid or its mixture with one or more other organic acids) in an amount (about 0.01-10 wt.%) enabling to maintain the pH of the composition in the range of 2-5. The composition has a viscosity- preservation of >=80% based on an initial viscosity, even when stored for one month or longer under a high temperature of 40 deg.C.
People who received chemotherapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.